The multiple-award, indefinite-delivery/indefinite-quantity contract covers the development of manufacturing processes and analytical test procedures, regulatory services, manufacturing and product characterization in support of the development of biopharmaceutical drug candidates for infectious diseases, the National Institutes of Health said in a FedBizOpps notice.
The awardees are:
- Advanced Bioscience Laboratories
- CSRA’s Dynport Vaccine subsidiary
- Paragon Bioservices